Login Register Cart 0
Review Article

长非编码RNA MALAT1抑制神经元凋亡和神经炎症，同时刺激神经突起的生长及其与MiR-125b介导阿尔茨海默病中的PTGS2，CDK5和FOXQ1相关性

卷 26, 期 25, 2019

页: [4698 - 4708] 页: 11

弟呕挨: 10.2174/0929867326666190107163756

价格: $65

摘要

背景：化疗引起的周围神经病变（CIPN）被认为是治疗药物的严重副作用，治疗选择有限。 在细胞抑制性单药治疗中，癌症患者中CIPN的发生率约为3–7％，在多化学疗法中，其发生率高达38％。 在化疗治疗的第一个月内，发现CIPN的患病率为68％。 在某些情况下，CIPN可以在治疗完成后部分或全部解决； 在其他情况下，它可能会保留很长时间，并影响患者的生活质量。 目的：本研究的目的是提供有关CIPN管理可用治疗方案的最新数据。 材料和方法：ESMO（欧洲医学肿瘤学会），ASCO（美国临床肿瘤学会），ONS（肿瘤护理学会），NCI（国家癌症研究所）和NCCN（国家综合癌症）的最新指南 网路）进行审查并包含在手稿中。 结果：推荐使用三环抗抑郁药（TCA），选择性5-羟色胺去甲肾上腺素再摄取抑制剂（SSNRI），普瑞巴林和加巴喷丁作为一线治疗药物。 其他治疗选择作为第二线和第三线治疗（利多卡因贴片，辣椒素高浓度贴片，曲马多和强阿片类药物）； 然而，显示出较低的意义。 在使用大麻素，药物组合，抗癫痫药，抗抑郁药和局部用药方面未得出结论性的结果。 结论：TCA，其他抗抑郁药和阿片类药物可被推荐作为治疗方法。 但是，我们不能推荐理想的预防或治疗CIPN的治疗剂。 因此，CIPN继续对临床医生和我们的患者构成挑战。

关键词: CIPN，神经病，化学疗法，大麻，阿片类药物，TCA，SSNR1。

« Previous Next »
[1]
Jensen, T.S.; Baron, R.; Haanpää, M.; Kalso, E.; Loeser, J.D.; Rice, A.S.C.; Treede, R.D. A new definition of neuropathic pain. Pain, 2011, 152(10), 2204-2205.
[http://dx.doi.org/10.1016/j.pain.2011.06.017] [PMID: 21764514]
[2]
Umapathi, T.; Chaudhry, V. Toxic neuropathy. Curr. Opin. Neurol., 2005, 18(5), 574-580.
[http://dx.doi.org/10.1097/01.wco.0000180158.34713.aa] [PMID: 16155443]
[3]
Addington, J.; Freimer, M. Chemotherapy-induced periph- eral neuropathy: an update on the current understanding. F1000 Res., 2016, 5, 1466.
[4]
Kanbayashi, Y.; Hosokawa, T. Peripheral neuropathies especially in cancer patients: focus on chemotherapy- induced peripheral neuropathies and post-herpetic neuralgia. Int. J. Cancer Res. Prev., 2015, 8(4), 8566.
[5]
Grisold, W.; Cavaletti, G.; Windebank, A.J. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro-oncol., 2012, 14(Suppl. 4), iv45-iv54.
[http://dx.doi.org/10.1093/neuonc/nos203] [PMID: 23095830]
[6]
Massey, R.L.; Kim, H.K.; Abdi, S. Brief review: chemotherapy-induced painful peripheral neuropathy (CIPPN): current status and future directions. Can. J. Anaesth., 2014, 61(8), 754-762.
[http://dx.doi.org/10.1007/s12630-014-0171-4] [PMID: 24804574]
[7]
Renn, C.L.; Carozzi, V.A.; Rhee, P.; Gallop, D.; Dorsey, S.G.; Cavaletti, G. Multimodal assessment of painful peripheral neuropathy induced by chronic oxaliplatin-based chemotherapy in mice. Mol. Pain, 2011, 7, 29.
[http://dx.doi.org/10.1186/1744-8069-7-29] [PMID: 21521528]
[8]
Sisignano, M.; Baron, R.; Scholich, K.; Geisslinger, G. Mechanism-based treatment for chemotherapy-induced peripheral neuropathic pain. Nat. Rev. Neurol., 2014, 10(12), 694-707.
[http://dx.doi.org/10.1038/nrneurol.2014.211] [PMID: 25366108]
[9]
Flatters, S.J.L.; Dougherty, P.M.; Colvin, L.A. Clinical and preclinical perspectives on Chemotherapy-Induced Peripheral Neuropathy (CIPN): a narrative review. Br. J. Anaesth., 2017, 119(4), 737-749.
[http://dx.doi.org/10.1093/bja/aex229] [PMID: 29121279]
[10]
Rostock, M.; Jaroslawski, K.; Guethlin, C.; Ludtke, R.; Schröder, S.; Bartsch, H.H. Chemotherapy-induced peripheral neuropathy in cancer patients: a four-arm randomized trial on the effectiveness of electroacupuncture. Evid. Based Complement. Alternat. Med., 2013, 2013349653
[http://dx.doi.org/10.1155/2013/349653] [PMID: 24066010]
[11]
Pachman, D.R.; Watson, J.C.; Lustberg, M.B.; Wagner-Johnston, N.D.; Chan, A.; Broadfield, L.; Cheung, Y.T.; Steer, C.; Storey, D.J.; Chandwani, K.D.; Paice, J.; Jean-Pierre, P.; Oh, J.; Kamath, J.; Fallon, M.; Strik, H.; Koeppen, S.; Loprinzi, C.L. Management options for established chemotherapy-induced peripheral neuropathy. Support. Care Cancer, 2014, 22(8), 2281-2295.
[http://dx.doi.org/10.1007/s00520-014-2289-x] [PMID: 24879391]
[12]
Wolf, S.L.; Barton, D.L.; Qin, R.; Wos, E.J.; Sloan, J.A.; Liu, H.; Aaronson, N.K.; Satele, D.V.; Mattar, B.I.; Green, N.B.; Loprinzi, C.L. The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA. Support. Care Cancer, 2012, 20(3), 625-632.
[http://dx.doi.org/10.1007/s00520-011-1141-9] [PMID: 21479990]
[13]
Gewandter, J.S.; Fan, L.; Magnuson, A.; Mustian, K. Pep- pone, L.; Heckler, C.; Hopkins, J.; Tejani, M.; Morrow, G.R.; Mohile, S.G. Falls and functional impairments in cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN): A University of Rochester CCOP study. Support. Care Cancer, 2013, 21(7), 2059-2066.
[http://dx.doi.org/10.1007/s00520-013-1766-y] [PMID: 23446880]
[14]
Loprinzi, C.L.; Reeves, B.N.; Dakhil, S.R.; Sloan, J.A.; Wolf, S.L.; Burger, K.N.; Kamal, A.; Le-Lindqwister, N.A.; Soori, G.S.; Jaslowski, A.J.; Novotny, P.J.; Lachance, D.H. Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. J. Clin. Oncol., 2011, 29(11), 1472-1478.
[http://dx.doi.org/10.1200/JCO.2010.33.0308] [PMID: 21383290]
[15]
Taillibert, S.; Le Rhun, E.; Chamberlain, M.C. Chemotherapy-related neurotoxicity. Curr. Neurol. Neurosci. Rep., 2016, 16(9), 81.
[http://dx.doi.org/10.1007/s11910-016-0686-x] [PMID: 27443648]
[16]
Cata, J.P.; Weng, H.R.; Lee, B.N.; Reuben, J.M.; Dougherty, P.M. Clinical and experimental findings in humans and animals with chemotherapy-induced peripheral neuropathy. Minerva Anestesiol., 2006, 72(3), 151-169.
[PMID: 16493391]
[17]
Park, S.B.; Krishnan, A.V.; Lin, C.S.; Goldstein, D.; Friedlander, M.; Kiernan, M.C. Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. Curr. Med. Chem., 2008, 15(29), 3081-3094.
[http://dx.doi.org/10.2174/092986708786848569] [PMID: 19075655]
[18]
Han, Y.; Smith, M.T. Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN). Front. Pharmacol., 2013, 4, 156.
[http://dx.doi.org/10.3389/fphar.2013.00156] [PMID: 24385965]
[19]
Pignataro, R.M.; Swisher, A.K. Chemotherapy induced peripheral neuropathy: risk factors, pathophysiology, assessment, and potential physical therapy interventions. Rehabil. Oncol., 2010, 28(2), 10-18.
[http://dx.doi.org/10.1097/01893697-201028020-00002]
[20]
Hershman, D.L.; Lacchetti, C.; Dworkin, R.H.; Lavoie Smith, E.M.; Bleeker, J.; Cavaletti, G.; Chauhan, C.; Gavin, P.; Lavino, A.; Lustberg, M.B.; Paice, J.; Schneider, B.; Smith, M.L.; Smith, T.; Terstriep, S.; Wagner-Johnston, N.; Bak, K.; Loprinzi, C.L. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J. Clin. Oncol., 2014, 32(18), 1941-1967.
[http://dx.doi.org/10.1200/JCO.2013.54.0914] [PMID: 24733808]
[21]
Visovsky, C.; Collins, M.; Abbott, L.; Aschenbrenner, J.; Hart, C. Putting evidence into practice: evidence-based interventions for chemotherapy-induced peripheral neuropathy. Clin. J. Oncol. Nurs., 2007, 11(6), 901-913.
[http://dx.doi.org/10.1188/07.CJON.901-913] [PMID: 18063548]
[22]
Wolf, S.; Barton, D.; Kottschade, L.; Grothey, A.; Loprinzi, C. Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur. J. Cancer, 2008, 44(11), 1507-1515.
[http://dx.doi.org/10.1016/j.ejca.2008.04.018] [PMID: 18571399]
[23]
Kajih, R.N.; Moore, C.D. Management of chemotherapy- induced peripheral neuropathy. US Pharm., 2015, 40(1), HS5-HS10.
[24]
Gamelin, L.; Boisdron-Celle, M.; Delva, R.; Guérin-Meyer, V.; Ifrah, N.; Morel, A.; Gamelin, E. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin. Cancer Res., 2004, 10(12 Pt 1), 4055-4061.
[http://dx.doi.org/10.1158/1078-0432.CCR-03-0666] [PMID: 15217938]
[25]
Durand, J.P.; Deplanque, G.; Montheil, V.; Gornet, J.M.; Scotte, F.; Mir, O.; Cessot, A.; Coriat, R.; Raymond, E.; Mitry, E.; Herait, P.; Yataghene, Y.; Goldwasser, F. Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. Ann. Oncol., 2012, 23(1), 200-205.
[http://dx.doi.org/10.1093/annonc/mdr045] [PMID: 21427067]
[26]
Piccolo, J.; Kolesar, J.M. Prevention and treatment of chemotherapy-induced peripheral neuropathy. Am. J. Health Syst. Pharm., 2014, 71(1), 19-25.
[http://dx.doi.org/10.2146/ajhp130126] [PMID: 24352178]
[27]
Salehi, Z.; Roayaei, M. Effect of vitamin E on oxaliplatin- induced peripheral neuropathy prevention: a randomized controlled trial. Int. J. Prev. Med., 2015, 6, 104.
[http://dx.doi.org/10.4103/2008-7802.169021] [PMID: 26682028]
[28]
Finnerup, N.B.; Attal, N.; Haroutounian, S.; McNicol, E.; Baron, R.; Dworkin, R.H.; Gilron, I.; Haanpää, M.; Hansson, P.; Jensen, T.S.; Kamerman, P.R.; Lund, K.; Moore, A.; Raja, S.N.; Rice, A.S.; Rowbotham, M.; Sena, E.; Siddall, P.; Smith, B.H.; Wallace, M. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol., 2015, 14(2), 162-173.
[http://dx.doi.org/10.1016/S1474-4422(14)70251-0] [PMID: 25575710]
[29]
Smith, E.M.; Pang, H.; Cirrincione, C.; Fleishman, S.; Paskett, E.D.; Ahles, T.; Bressler, L.R.; Fadul, C.E.; Knox, C.; Le-Lindqwister, N.; Gilman, P.B.; Shapiro, C.L. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA, 2013, 309(13), 1359-1367.
[http://dx.doi.org/10.1001/jama.2013.2813] [PMID: 23549581]
[30]
Kanat, O.; Ertas, H.; Caner, B. Platinum-induced neurotoxicity: a review of possible mechanisms. World J. Clin. Oncol., 2017, 8(4), 329-335.
[http://dx.doi.org/10.5306/wjco.v8.i4.329] [PMID: 28848699]
[31]
Majithia, N.; Temkin, S.M.; Ruddy, K.J.; Beutler, A.S.; Hershman, D.L.; Loprinzi, C.L. National Cancer Institute-supported chemotherapy-induced peripheral neuropathy trials: outcomes and lessons. Support. Care Cancer, 2016, 24(3), 1439-1447.
[http://dx.doi.org/10.1007/s00520-015-3063-4] [PMID: 26686859]
[32]
Stubblefield, M.D.; Burstein, H.J.; Burton, A.W.; Custodio, C.M.; Deng, G.E.; Ho, M.; Junck, L.; Morris, G.S.; Paice, J.A.; Tummala, S.; Von Roenn, J.H. NCCN task force report: management of neuropathy in cancer. J. Natl. Compr. Canc. Netw., 2009, 7(Suppl. 5), S1-S26.
[http://dx.doi.org/10.6004/jnccn.2009.0078] [PMID: 19755042]
[33]
Kong, V.K.; Irwin, M.G. Adjuvant analgesics in neuropathic pain. Eur. J. Anaesthesiol., 2009, 26(2), 96-100.
[http://dx.doi.org/10.1097/EJA.0b013e328318c706] [PMID: 19142081]
[34]
Portenoy, R.K. Adjuvant analgesics in pain management. In: Textbook of Palliative Medicine; B.R. Ferrell and Nessa Coyle, Eds; Oxford University Press, Oxford. , 2010; p. 361.
[35]
Dworkin, R.H.; O’Connor, A.B.; Audette, J.; Baron, R.; Gourlay, G.K.; Haanpää, M.L.; Kent, J.L.; Krane, E.J. Le- Bel, A.A.; Levy, R.M.; Mackey, S.C.; Mayer, J.; Miask- owski, C.; Raja, S.N.; Rice, A.S.C.; Schmader, K.E.; Stacey, B.; Stanos, S.; Treede, R.D.; Turk, D.C.; Walco, G.A.; Wells, C.D. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin. Proc., 2010, 85(3)(Suppl.), S3-S14.
[http://dx.doi.org/10.4065/mcp.2009.0649] [PMID: 20194146]
[36]
Fornasari, D. Pharmacotherapy for neuropathic pain: a review. Pain Ther., 2017, 6(S1)(Suppl. 1), 25-33.
[http://dx.doi.org/10.1007/s40122-017-0091-4] [PMID: 29178034]
[37]
Atreya, S. Pregabalin in chemotherapy induced neuropathic pain. Indian J. Palliat. Care, 2016, 22(1), 101-103.
[http://dx.doi.org/10.4103/0973-1075.173941] [PMID: 26962289]
[38]
Xiao, W.; Boroujerdi, A.; Bennett, G.J.; Luo, Z.D. Chemotherapy-evoked painful peripheral neuropathy: analgesic effects of gabapentin and effects on expression of the alpha-2-delta type-1 calcium channel subunit. Neuroscience, 2007, 144(2), 714-720.
[http://dx.doi.org/10.1016/j.neuroscience.2006.09.044] [PMID: 17084535]
[39]
Rao, R.D.; Michalak, J.C.; Sloan, J.A.; Loprinzi, C.L.; Soori, G.S.; Nikcevich, D.A.; Warner, D.O.; Novotny, P.; Kutteh, L.A.; Wong, G.Y. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer, 2007, 110(9), 2110-2118.
[http://dx.doi.org/10.1002/cncr.23008] [PMID: 17853395]
[40]
Hausheer, F.H.; Schilsky, R.L.; Bain, S.; Berghorn, E.J.; Lieberman, F. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin. Oncol., 2006, 33(1), 15-49.
[http://dx.doi.org/10.1053/j.seminoncol.2005.12.010] [PMID: 16473643]
[41]
Saarto, T.; Wiffen, P.J. Antidepressants for neuropathic pain. Cochrane Database Syst. Rev., 2005, (3)CD005454
[PMID: 16034979]
[42]
Gewandter, J.S.; Mohile, S.G.; Heckler, C.E.; Ryan, J.L.; Kirshner, J.J.; Flynn, P.J.; Hopkins, J.O.; Morrow, G.R. A phase III randomized, placebo-controlled study of topical amitriptyline and ketamine for chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study of 462 cancer survivors. Support. Care Cancer, 2014, 22(7), 1807-1814.
[http://dx.doi.org/10.1007/s00520-014-2158-7] [PMID: 24531792]
[43]
Ocean, A.J.; Vahdat, L.T. Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies. Support. Care Cancer, 2004, 12(9), 619-625.
[http://dx.doi.org/10.1007/s00520-004-0657-7] [PMID: 15258838]
[44]
Aziz, M.T.; Good, B.L.; Lowe, D.K. Serotonin-norepinephrine reuptake inhibitors for the management of chemotherapy-induced peripheral neuropathy. Ann. Pharmacother., 2014, 48(5), 626-632.
[http://dx.doi.org/10.1177/1060028014525033] [PMID: 24577146]
[45]
Yang, Y.H.; Lin, J.K.; Chen, W.S.; Lin, T.C.; Yang, S.H.; Jiang, J.K.; Chang, S.C.; Lan, Y.T.; Lin, C.C.; Yen, C.C.; Tzeng, C.H.; Wang, W.S.; Chiang, H.L.; Teng, C.J.; Teng, H.W. Duloxetine improves oxaliplatin-induced neuropathy in patients with colorectal cancer: an open-label pilot study. Support. Care Cancer, 2012, 20(7), 1491-1497.
[http://dx.doi.org/10.1007/s00520-011-1237-2] [PMID: 21814779]
[46]
Otake, A.; Yoshino, K.; Ueda, Y.; Sawada, K.; Mabuchi, S.; Kimura, T.; Kobayashi, E.; Isobe, A.; Egawa-Takata, T.; Matsuzaki, S.; Fujita, M.; Kimura, T. Usefulness of duloxetine for Paclitaxel-induced peripheral neuropathy treatment in gynecological cancer patients. Anticancer Res., 2015, 35(1), 359-363.
[PMID: 25550572]
[47]
Fallon, M.T.; Storey, D.J.; Krishan, A.; Weir, C.J.; Mitchell, R.; Fleetwood-Walker, S.M.; Scott, A.C.; Colvin, L.A. Cancer treatment-related neuropathic pain: proof of concept study with menthol--a TRPM8 agonist. Support. Care Cancer, 2015, 23(9), 2769-2777.
[http://dx.doi.org/10.1007/s00520-015-2642-8] [PMID: 25680765]
[48]
Üçeyler, N.; Sommer, C. High-dose capsaicin for the treatment of neuropathic pain: what we know and what we need to know. Pain Ther., 2014, 3(2), 73-84.
[http://dx.doi.org/10.1007/s40122-014-0027-1] [PMID: 25069571]
[49]
Barton, D.L.; Wos, E.J.; Qin, R.; Mattar, B.I.; Green, N.B.; Lanier, K.S.; Bearden, J.D., III; Kugler, J.W.; Hoff, K.L.; Reddy, P.S.; Rowland, K.M., Jr; Riepl, M.; Christensen, B.; Loprinzi, C.L. A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. Support. Care Cancer, 2011, 19(6), 833-841.
[http://dx.doi.org/10.1007/s00520-010-0911-0] [PMID: 20496177]
[50]
Attal, N.; Cruccu, G.; Baron, R.; Haanpää, M.; Hansson, P.; Jensen, T.S.; Nurmikko, T. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur. J. Neurol., 2010, 17(9), 1113-e88.
[http://dx.doi.org/10.1111/j.1468-1331.2010.02999.x] [PMID: 20402746]
[51]
Liu, Y.C.; Wang, W.S. Human mu-opioid receptor gene A118G polymorphism predicts the efficacy of tramadol/acetaminophen combination tablets (ultracet) in oxaliplatin-induced painful neuropathy. Cancer, 2012, 118(6), 1718-1725.
[http://dx.doi.org/10.1002/cncr.26430] [PMID: 21837673]
[52]
Bennett, M.I. Effectiveness of antiepileptic or antidepressant drugs when added to opioids for cancer pain: systematic review. Palliat. Med., 2011, 25(5), 553-559.
[http://dx.doi.org/10.1177/0269216310378546] [PMID: 20671006]
[53]
Wiffen, P.J.; Derry, S.; Bell, R.F.; Rice, A.S.; Tölle, T.R.; Phillips, T.; Moore, R.A. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst. Rev., 2017, 6CD007938
[http://dx.doi.org/10.1002/14651858.CD007938.pub4] [PMID: 28597471]
[54]
Nagashima, M.; Ooshiro, M.; Moriyama, A.; Sugishita, Y.; Kadoya, K.; Sato, A.; Kitahara, T.; Takagi, R.; Urita, T.; Yoshida, Y.; Tanaka, H.; Oshiro, T.; Okazumi, S.; Katoh, R. Efficacy and tolerability of controlled-release oxycodone for oxaliplatin-induced peripheral neuropathy and the extension of FOLFOX therapy in advanced colorectal cancer patients. Support. Care Cancer, 2014, 22(6), 1579-1584.
[http://dx.doi.org/10.1007/s00520-014-2132-4] [PMID: 24452412]
[55]
Brzeziński, K. Chemotherapy-induced peripheral neuropathy. Part II. Prevention. Contemp. Oncol. (Pozn.), 2012, 16(3), 258-261.
[http://dx.doi.org/10.5114/wo.2012.29296] [PMID: 23788891]
[56]
Moore, R.J.; Groninger, H. Chemotherapy-induced peripheral neuropathy in pediatric cancer patients. Cureus, 2013, 5(6)e124
[PMID: 25144779]
[57]
Nishikawa, T.; Hasegawa, K.; Shintani, D.; Yano, Y.; Sato, S.; Yabuno, A.; Kurosaki, A.; Yoshida, H.; Fujiwara, K. Combination therapy of pregabalin with tramadol for treat- ment of peripheral neuropathy in patients with gynecological cancer receiving taxane containing chemotherapy. Gan To Kagaku Ryoho, 2017, 44(3), 227-231.
[PMID: 28292992]
[58]
Schröder, S.; Beckmann, K.; Franconi, G.; Meyer-Hamme, G.; Friedemann, T.; Greten, H.J.; Rostock, M.; Efferth, T. Can medical herbs stimulate regeneration or neuroprotection and treat neuropathic pain in chemotherapy-induced peripheral neuropathy? Evid. Based Complement. Alternat. Med., 2013.2013423713
[http://dx.doi.org/10.1155/2013/423713] [PMID: 23983777]
[59]
Wilsey, B.; Marcotte, T.; Deutsch, R.; Gouaux, B.; Sakai, S.; Donaghe, H. Low-dose vaporized cannabis significantly improves neuropathic pain. J. Pain, 2013, 14(2), 136-148.
[http://dx.doi.org/10.1016/j.jpain.2012.10.009] [PMID: 23237736]
[60]
Wilsey, B.; Marcotte, T.D.; Deutsch, R.; Zhao, H.; Prasad, H.; Phan, A. An exploratory human laboratory experiment evaluating vaporized cannabis in the treatment of neuropathic pain from spinal cord injury and disease. J. Pain, 2016, 17(9), 982-1000.
[http://dx.doi.org/10.1016/j.jpain.2016.05.010] [PMID: 27286745]
[61]
Swift, W.; Gates, P.; Dillon, P. Survey of Australians using cannabis for medical purposes. Harm Reduct. J., 2005, 2, 18.
[http://dx.doi.org/10.1186/1477-7517-2-18] [PMID: 16202145]
[62]
King, K.M.; Myers, A.M.; Soroka-Monzo, A.J.; Tuma, R.F.; Tallarida, R.J.; Walker, E.A.; Ward, S.J. Single and combined effects of Δ9 -tetrahydrocannabinol and cannabidiol in a mouse model of chemotherapy-induced neuropathic pain. Br. J. Pharmacol., 2017, 174(17), 2832-2841.
[http://dx.doi.org/10.1111/bph.13887] [PMID: 28548225]
[63]
Thompson, D.F.; Brooks, K.G. Systematic review of topical amitriptyline for the treatment of neuropathic pain. J. Clin. Pharm. Ther., 2015, 40(5), 496-503.
[http://dx.doi.org/10.1111/jcpt.12297] [PMID: 26059975]
[64]
Tsavaris, N.; Kopterides, P.; Kosmas, C.; Efthymiou, A.; Skopelitis, H.; Dimitrakopoulos, A.; Pagouni, E.; Pikazis, D.; Zis, P.V.; Koufos, C. Gabapentin monotherapy for the treatment of chemotherapy-induced neuropathic pain: a pilot study. Pain Med., 2008, 9(8), 1209-1216.
[http://dx.doi.org/10.1111/j.1526-4637.2007.00325.x] [PMID: 19067834]
[65]
Verma, V.; Singh, N.; Singh Jaggi, A. Pregabalin in neuropathic pain: evidences and possible mechanisms. Curr. Neuropharmacol., 2014, 12(1), 44-56.
[http://dx.doi.org/10.2174/1570159X1201140117162802] [PMID: 24533015]
[66]
Derry, S.; Moore, R.A. Topical capsaicin (low concentration) for chronic neuropathic pain in adults. Cochrane Database Syst. Rev., 2012, (9)CD010111
[http://dx.doi.org/10.1002/14651858.CD010111] [PMID: 22972149]
[67]
Duehmke, R.M.; Derry, S.; Wiffen, P.J.; Bell, R.F.; Aldington, D.; Moore, R.A. Tramadol for neuropathic pain in adults. Cochrane Database Syst. Rev., , 2017, 6CD003726.
[PMID: 28616956]
[68]
Visovsky, C.; Collins, M.; Abbott, L.; Aschenbrenner, J.; Hart, C. Putting evidence into practice: evidence-based interventions for chemotherapy-induced peripheral neuropathy. Clin. J. Oncol. Nurs., 2007, 11(6), 901-913.
[http://dx.doi.org/10.1188/07.CJON.901-913] [PMID: 18063548]
[69]
Tofthagen, C.; Visovsky, C.M.; Hopgood, R. Chemotherapy-induced peripheral neuropathy: an algorithm to guide nursing management. Clin. J. Oncol. Nurs., 2013, 17(2), 138-144.
[http://dx.doi.org/10.1188/13.CJON.138-144] [PMID: 23538249]
[70]
Andrade, D.C.D.; Teixeira, M.J.; Galhardoni, R.; Ferreira, K.A.S.L.; Malieno, P.B.; Scisci, N.; Riechelmann, R.P.; Teixeira, W.G.J.; Saragiotto, D.F.; Silva, V.A.; Raicher, I.; Castro, I.D.; Parravano, D.; Fukushima, J.T.; Lefaucheur, J.P.; Bouhassira, D. Macarenco. R.Se.S.; Mello, E.S.D.; Hoff, P.M. A phase III, randomized, double-blind, placebo- controlled trial to evaluate the efficacy and safety of pre- gabalin in the prevention and reduction of oxaliplatin- induced painful neuropathy (PreOx). J. Clin. Oncol., 2015, 33(15)(Suppl.), 3575-3575.
[71]
Desideri, I.; Francolini, G.; Becherini, C.; Terziani, F. Delli- Paoli C.; Olmetto E.; Loi M.; Perna M.; Meattini I.; Scotti V.; Greto D.; Bonomo P.; Sulprizio S.; Livi L. Use of an alpha lipoic, methylsulfonylmethane and bromelaindietary suplement (Opera®) for chemotherapy-induced peripheral neuropathy management, a prospectivestudy. Med. Oncol., 2017, 34(3), 46.
[http://dx.doi.org/10.1007/s12032-017-0907-4] [PMID: 28205185]
[72]
Ripamonti, C.I.; Santini, D.; Maranzano, E.; Berti, M.; Roila, F. Management of cancer pain: ESMO Clinical Practice Guidelines. Ann. Oncol., 2012, 23(Suppl. 7), vii139-vii 154..
[http://dx.doi.org/10.1093/annonc/mds233] [PMID: 22997447]
[73]
National Cancer Institute. Common Terminology Criteria for Adverse Events v5.0. NCI, NIH, DHHS. November 27 2017.
[74]
World Alliance for Patient Safety. WHO Draft Guidelines for Adverse Event Reporting and Learning Systems., Geneva:World Health Organization.(WHO/EIP/SPO/QPS/05.3). . 2005.
[75]
International Organization for Standardization. 1988 ISO Standards Handbook 1, 3rd Edition. Documentation and information. Switzerland: ISO in World Health Organication Family of International Classifications, June. , 2004.
[76]
Katzung, B.G.; Masters, S.B.; Trevor, A.J. Basic and clinical pharmacology, 12th ed; , 2012.
[77]
Blackwell, B. Adverse effects of antidepressant drugs. Part 1: monoamine oxidase inhibitors and tricyclics. Drugs, 1981, 21(3), 201-219.
[http://dx.doi.org/10.2165/00003495-198121030-00002] [PMID: 6114849]

Rights & Permissions Print Cite
Article Metrics
111
10
© 2024 Bentham Science Publishers | Privacy Policy